Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease, in a deal worth up to $50 million in biobucks. Since the buy was announced, Organovo’s stock has skyrocketed 244%.
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease, in a deal worth up to $50 million in biobucks. Since the buy was announced, Organovo’s stock has skyrocketed 244%.
